AI in Pharma & Biotech: 36 real deployments

AI agent selecting gene therapy candidates and computing stereotactic injection coordinates

Initial partner in OpenAI's trusted-access program for GPT-6 Rosalind Research for biology and drug discovery

Initial partner in OpenAI's trusted-access program for GPT-6 Rosalind Research for biology and drug discovery

Initial partner in OpenAI's trusted-access program for GPT-6 Rosalind Research for biology and drug discovery

Claude-powered drug-discovery partnership with Anthropic

Claude-powered drug-discovery partnership with Anthropic

Claude-powered drug-discovery partnership with Anthropic

Claude-powered drug-discovery partnership with Anthropic

Claude-powered drug-discovery partnership with Anthropic

Claude-powered drug-discovery partnership with Anthropic

Used Claude to coordinate 11 external labs and advance a muscular dystrophy candidate through preclinical research

Reported: Promising mouse results achieved in under 18 months; candidate could enter human trials by late 2028

Using Lunit's SCOPE IO AI pathology platform for biomarker discovery and patient stratification across five tumor types in ivonescimab clinical development

Partnering with Pathos AI to apply the Foundry model to Alzheimer's drug discovery

Running Foundry model with thousands of agents to score clinical candidates in oncology, expanding into neurology using new Tempus AI datasets

Designs de novo miniprotein therapeutics using AI against multiple targets selected by Astellas Innovation Management under a research and licensing collaboration worth over $400M upfront plus milestones and royalties

64-hour autonomous campaign using Claude across 12 tools to generate 318,484 protein designs and screen 553,000 design-toxin pairs against scorpion neurotoxins on four human prompts

Reported: 17 of 211 lab-tested designs bound to neurotoxins; two Cn2 binders hit single-digit nanomolar affinity and competed with a known neutralizing antibody

Agentic operating layer via Orchestra Bio acquisition for scientists and AI agents to jointly manage drug programs, monitoring studies, tracking timelines, and flagging delays; folded into Rosalind life-sciences suite launched with a 30-seat academic plan

Piloting Oracle AI combined with real-world healthcare data to identify eligible clinical trial patients and monitor safety signals, with first project a hypertension study in Abu Dhabi with M42

applying its Virtual Human AI platform to drive MASH and cardiomyopathy target discovery through development candidate for AstraZeneca under a $40M upfront deal worth up to ~$1.46B in milestones

using insitro's Virtual Human AI platform to identify and advance drug targets in MASH and cardiomyopathies through development candidate stage

Using Albert Invent's chemistry-native AI trained on 15M molecular structures and the full corpus of chemical patents for chemistry research and formulation

Used PandaOmics and Chemistry42 AI systems to design PROTAC molecules targeting Bruton's tyrosine kinase for leukemias and lymphomas

Reported: AI-driven pipeline collapsed drug selection to 12-18 months versus 2.5-4 years with traditional methods; results published in the Journal of Medicinal Chemistry

Using PRISM natural-product AI platform to discover drug candidates and advance them through clinical trials

Reported: positive early readouts from ENV-294 (atopic dermatitis) and ENV-308 (metabolic health)

Using Anthropic's Claude models, starting with Claude Science on specific R&D workflows, to accelerate drug discovery and AI-driven software development across the company

Using AI to design small molecules targeting previously undruggable proteins for drug discovery

Reported: unveiled an AI-designed small molecule targeting the previously undruggable IL-17 protein

using in-house locked-down AI models for preclinical drug discovery

Anthropic is partnering with the Gates Foundation on vaccine development and crop-dataset work

Using ChatGPT and AlphaFold to design personalized mRNA cancer vaccines for dogs, with clinical trials underway

Eli Lilly runs AI-driven drug discovery at pharma scale on dedicated supercomputing infrastructure under Chief AI Officer Thomas Fuchs.

Amgen, Moderna, the Allen Institute, and Thermo Fisher received OpenAI's GPT-Rosalind vertical reasoning model as a research preview for drug discovery and genomics work.

Novo Nordisk partnered with OpenAI to overhaul drug development, with pilots starting immediately in R&D, manufacturing, and commercial and full integration planned by year-end.

Deployed Microsoft Copilot across the organization in what Boehringer describes as one of pharma's largest Copilot deployments

using Hang Ten Systems AI platform for enterprise modernization

Merck committed up to $1B to Google Cloud for an enterprise AI backbone covering R&D, manufacturing, commercial, and corporate functions.

Integrating Estima Scientific's AI-powered health economics and outcomes research tools into EVERSANA's market access suite for AI-driven economic modeling and evidence synthesis for pharmaceutical clients

Applies SCOPE IO AI pathology platform to H&E whole-slide images for tumor microenvironment analysis and biomarker discovery in Summit Therapeutics' ivonescimab trials across NSCLC, colorectal, urothelial, head-and-neck, and biliary tract cancers